Comparing Survival after Resection of Pancreatic Cancer with and without Pancreatic Cysts: Nationwide Registry-Based Study
Authors:
- Myrte GorrisMGMyrte Gorris
- Nadine C. M. van HuijgevoortNHNadine C. M. van Huijgevoort
- Arantza FarinaAFArantza Farina
- Lodewijk A. A. BrosensLBLodewijk A. A. Brosens
- Hjalmar C. van SantvoortHSHjalmar C. van Santvoort
- Bas Groot KoerkampBKBas Groot Koerkamp
- Marco J. BrunoMarco J. Bruno
- Marc G. BesselinkMBMarc G. Besselink
- Jeanin E. van HooftJHJeanin E. van Hooft
Open Access
Abstract
Background: Outcome after resection of pancreatic ductal adenocarcinoma associated with pancreatic cystic neoplasms (PCN-PDAC) might differ from PDAC not associated with PCN. This nationwide, registry-based study aimed to compare the overall survival (OS) in these patients. Methods: Data from consecutive patients after pancreatic resection for PDAC between 2013 and 2018 were matched with the corresponding pathology reports. Primary outcome was OS for PCN-PDAC and PDAC including 1-year and 5-year OS. Cox regression analysis was used to correct for prognostic factors (e.g., pT-stage, pN-stage, and vascular invasion). Results: In total, 1994 patients underwent resection for PDAC including 233 (12%) with PCN-PDAC. Median estimated OS was better in patients with PCN-PDAC (34.5 months [95%CI 25.6 to 43.5]) as compared to PDAC not associated with PCN (18.2 months [95%CI 17.3 to 19.2]; hazard ratio 0.53 [95%CI 0.44–0.63]; p < 0.001). The difference in OS remained after correction for prognostic factors (adjusted hazard ratio 1.58 [95%CI 1.32−1.90]; p < 0.001). Conclusions: This nationwide registry-based study showed that 12% of resected PDAC were PCN-associated. Patients with PCN-PDAC had better OS as compared to PDAC not associated with PCN.Keywords
This publication has 18 references indexed in Scilit:
- Role of postoperative adjuvant therapy in resected invasive intraductal papillary mucinous neoplasm of the pancreas: A multicenter external validationJournal of Hepato-Biliary-Pancreatic Sciences, 2021
- IPMNs with co-occurring invasive cancers: neighbours but not always relativesGut, 2018
- Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreasPancreatology, 2017
- Pancreatic resection for intraductal papillary mucinous neoplasm– a thirteen-year single center experienceBMC Cancer, 2016
- A Revised Classification System and Recommendations From the Baltimore Consensus Meeting for Neoplastic Precursor Lesions in the PancreasAmerican Journal of Surgical Pathology, 2015
- Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2015
- Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United StatesCancer Research, 2014
- Pancreatic Ductal Adenocarcinoma Derived From IPMN and Pancreatic Ductal Adenocarcinoma Concomitant With IPMNPancreas, 2011
- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies*2007
- Pathology Databanking and Biobanking in The Netherlands, a Central Role for PALGA, the Nationwide Histopathology and Cytopathology Data Network and ArchiveAnalytical Cellular Pathology, 2007